Structure via PubChem · Public domain (PubChem)
larotrectinib
Sign in to saveAlso known as (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, example 14 [US8865698 B2], larotrectinib (proposed INN), LOXO-101, ARRY-470
Larotrectinib, sold under the brand name Vitrakvi, is a medication for the treatment of cancer. It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013.
Chemical data
- Formula
- C21H22F2N6O2
- Molecular weight
- 428.4 g/mol
- IUPAC name
- (3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide
- SMILES
- C1C[C@@H](N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CC[C@@H](C4)O)C5=C(C=CC(=C5)F)F
- InChIKey
- NYNZQNWKBKUAII-KBXCAEBGSA-N
- XLogP
- 1.7
- Polar surface area
- 86 Ų
- H-bond donors
- 2
- H-bond acceptors
- 7
- Formal charge
- 0
via PubChem
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 428.17723
Show 6 more facts
- chemical formula
- C₂₁H₂₂F₂N₆O₂
- canonical SMILES
- C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F
- isomeric SMILES
- C1C[C@@H](N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CC[C@@H](C4)O)C5=C(C=CC(=C5)F)F
- World Health Organisation international non-proprietary name
- larotrectinib
- subject has role
- protein kinase inhibitors
- medical condition treated
- cancer
via Wikidata · CC0
~3 min read
Encyclopedic overview
3 sectionsContents
- Research
- References
- External links
{{Infobox drug | image = Larotrectinib.svg | image_class = skin-invert-image | alt = | caption =
| pronounce = | tradename = Vitrakvi | Drugs.com = | MedlinePlus = a619006 | DailyMedID = Larotrectinib | pregnancy_AU = D | pregnancy_AU_comment = | pregnancy_category= | routes_of_administration = By mouth, oropharyngeal | class = | ATC_prefix = L01 | ATC_suffix = EX12
Excerpted from Wikipedia’s “larotrectinib” article, available under the CC BY-SA 4.0 licence.